Adrian David Marais

Prof. Adrian David Marais


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Pathology
Verified
Journal Article
Closed access
AMAdrian David Marais
Adrian David Marais

1 March 2008 in Atherosclerosis
Verified
Journal Article
Closed access
AMAdrian David Marais
Adrian David Marais
FRFrederick J. Raal
Frederick J. Raal
ESEvan A. Stein
Evan A. Stein
DRDaniel J. Rader
Daniel J. Rader
JBJames Blasetto
James Blasetto
WWWim Wilpshaar
Wim Wilpshaar

1 January 2015 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
AMAdrian David Marais
Adrian David Marais
JKJae B. Kim
Jae B. Kim
SWScott M. Wasserman
Scott M. Wasserman
GLGilles Lambert
Gilles Lambert

1 November 2006 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
AGAnouk Van Der Graaf
Anouk Van Der Graaf
MNMelchior C. Nierman
Melchior C. Nierman
JFJean C. Firth
Jean C. Firth
KWKaren H. Wolmarans
Karen H. Wolmarans
AMAdrian David Marais
Adrian David Marais
EGEric De Groot
Eric De Groot
Aim: To assess whether early initiation of statin therapy for heterozygous familial hypercholesterolaemia favourably affects lipid profiles or vascular morphological changes. Methods: Children and adolescents aged 10–16 y with heterozygous familial hypercholesterolaemia were administered fluvastatin (80 mg/d) for 2 y in a single‐arm two‐centre study. Carotid B‐mode intima‐media thickness (IMT) and M‐mode arterial wall stiffness (β) were recorded. Eighty of the 85 enrolled subjects completed the trial. Results: The median decrease in low‐density lipoprotein (LDL) cholesterol from baseline at last study visit was 33.9%; median decreases in total cholesterol, triglycerides and apolipoprotein B were 27.1%, 5.3% and 24.2%, respectively; the median increase in high‐density lipoprotein (HDL) cholesterol was 5.3%. Changes in carotid arterial wall thickness and stiffness versus baseline were fractional and statistically non‐significant (ΔIMT −0.005 mm, 95% CI −0.018 to +0.007 mm, n=83; and Δβ= 0.017, 95% CI −0.219 to +0.253, n=79). Adverse events, all non‐serious, were reported by 58 subjects (68.2%); four were suspected to be drug‐related. Change in hormone levels and sexual maturation were appropriate for this age group. Conclusion: Fluvastatin lowered LDL cholesterol, total cholesterol and apolipoprotein B levels effectively over a prolonged period in children and adolescents with heterozygous familial hypercholesterolaemia. Carotid IMT and wall stiffness remained largely unchanged.

1 February 2004
Verified
Journal Article
Closed access
AMAdrian David Marais
Adrian David Marais

10 May 2021 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
AMAdrian David Marais
Adrian David Marais